



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

September 15, 2025

James A. McNulty  
Interim Chief Financial Officer  
Inhibitor Therapeutics, Inc.  
3014 W. Palmira Avenue  
Suite 302  
Tampa, FL 33629

**Re: Inhibitor Therapeutics, Inc.**  
**Form 10-K for the Year Ended December 31, 2024**  
**Filed March 28, 2025**  
**File No. 001-13467**

Dear James A. McNulty:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences